A meta-analysis of large clinical trials involving patients with AF undergoing PCI revealed that dual therapy with an oral anticoagulant and P2Y12 inhibitor reduced bleeding events by 20–40% compared with triple therapy [30]. The gene discussed is P2RY12; the disease is atrial fibrillation.